  Dyslipidemia , and specifically elevated low-density lipoprotein ( LDL) cholesterol , is one of the most important cardiovascular risk factors. Statins are considered first line therapy for the primary and secondary prevention of cardiovascular disease. However , statins may not be adequate treatment for elevated circulating LDL levels and are ineffective in certain familial hypercholesterolemias. The discovery of proprotein convertase subtilisin/kexin type 9 ( PCSK9) , a regulatory protein that affects LDL receptors , offers a new alternative for these patients. Moreover , gain-of-function